Da Hee Han, PharmD

Most Recent Articles by Da Hee Han, PharmD

Bevyxxa Approved for Prophylaxis of Venous Thromboembolism

By Jun 23, 2017

The study examined efficacy in 7,441 patients according to a composite outcome score consisting of either the occurrence of asymptomatic or symptomatic proximal deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE), or VTE-related death

FDA Approves Combo Tx for Metastatic NSCLC with BRAF V600E Mutation

By Jun 23, 2017

The approval for Tafinlar and Mekinist combination therapy was based on a Phase 2 international, multicenter, 3-cohort, non-randomized, non-comparative, open-label trial (Study BRF113928) in patients with locally confirmed stage IV NSCLC with BRAF V600E mutation.

Ocrevus Effective in Reducing Multiple MS Progression Markers

By Jun 23, 2017

The post-hoc analyses found Ocrevus to significantly decrease disease activity and disability progression in patients with RMS and PPMS, as assessed by No Evidence of Progression or Active Disease (NEPAD), a new composite endpoint in MS.

Advanced Pharma Initiates Recall Following Hospira Recall Announcement

By Jun 23, 2017

The use of contaminated product may cause adverse events such as fever, chills and malaise; more serious adverse events include systemic bacterial sepsis and systemic invasive mycoses.

New Treatment Option for Hereditary Angioedema FDA-Approved

By Jun 23, 2017

The human plasma-derived, purified, pasteurized, lyophilized concentrate is derived from large pools of human plasma from U.S. donors.

More Articles by Da Hee Han, PharmD